

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/724,194	12/01/2003		John Fitzgerald Kokai-Kun	7787.0061-00	1338
28765	7590	05/25/2005		EXAMINER	
WINSTON			PORTNER, VIRGINIA ALLEN		
1700 K STREET, N.W. WASHINGTON, DC 20006				ART UNIT	PAPER NUMBER
	,			1645	
			DATE MAILED: 05/25/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
055 4-4' 0	10/724,194	KOKAI-KUN ET AL.					
Office Action Summary	Examiner	Art Unit					
	Ginny Portner	1645					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply if NO period for reply sis specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	i6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	ely filed will be considered timely. the mailing date of this communication. (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 01 De	ecember 2003.	•					
2a) ☐ This action is FINAL . 2b) ☐ This	This action is FINAL . 2b)⊠ This action is non-final.						
	, ,						
closed in accordance with the practice under E	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)	·						
Application Papers							
9) The specification is objected to by the Examiner	r.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the o	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correcting 11) The oath or declaration is objected to by the Expension 11.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Da 5) Notice of Informal Pa						

Application/Control Number: 10/724,194

Art Unit: 1645

DETAILED ACTION

Claims 1-38 are pending.

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-12, drawn to methods of treating with an antibody, classified in class
 424, subclass 165.1.
 - II. Claims 13-17, drawn to methods of treating with a staphylococcal antigen, specifically wall teichoic acid, classified in class 424, subclass 243.1.
 - III. Claims 18-30, drawn to compositions of antibodies, classified in class 530, subclass 388.2.
 - IV. Claims 31-36, drawn to compositions of staphylococcal antigen, specifically wall teichoic acid, classified in class 435, subclass 7.33.
 - V. Claims 37-38, drawn to compositions of mutant Staphylococcus aureus that are deficient in WTA antigen, classified in class 435, subclass 172.1.
- 2. Inventions Group II and Group I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that product, specifically, antibodies can be used in method of detecting antigen, in methods of purification of antigen and in methods of making anti-idiotypic antibodies.

Application/Control Number: 10/724,194

Art Unit: 1645

- 3. Inventions Group T and Group 1 are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that product, specifically the antigen can be used in methods of affinity purification of antibodies, in methods of diagnosis of active infection, to produce molecular image polymers.
- 4. Inventions Groups I, II and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions the mutant cells of Group V do not produce any teichoic acid to which the antibodies of Group I bind and do not comprise the teichoic acid antigen of Group II, therefore the inventions of Groups I and II and V evidence different modes of operation, function and effects.
- 5. Inventions Groups III and IV are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct from each other if they are shown to be separately usable. In the instant case, invention Group III has separate utility such as a diagnostic antibody, in methods of making an anti-idiotypic antibody and in methods of therapeutic treatment

Application/Control Number: 10/724,194 Page 4

Art Unit: 1645

6. Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37 CFR

1.143).

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a request under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i). See MPEP § 806.05(d).

8. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Ginny Portner whose telephone number is (571) 272-0862. The

examiner can normally be reached on M-F, alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Lynette Smith can be reached on (571) 272-0864.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

vgp May 19, 2005 LYNETTE R. F. SMITH
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600